Objective: Available evidence points to a role of cytochrome P450 (Cyp) drug biotransformation enzymes in central nervous system diseases, including epilepsy.
| INTRODUCTION
The concept of a bidirectional brain-periphery interplay occurring during physiological and pathological states is emerging. Experimental and clinical evidence supports a role of peripheral pathologies in favoring the onset or the progression of central nervous system (CNS) diseases. [1] [2] [3] However, less is known on whether CNS diseases may impact peripheral organs' function. A number of players exist to potentially sustain a cross talk during pathological conditions, including inflammatory signals, stress hormones, and cerebrovascular or neuronal routes. [4] [5] [6] [7] Abnormalities in pharmacokinetic mechanisms in epilepsy have been previously outlined. 8, 9 Recently, cytochrome metabolic enzymes (cytochrome P450 [Cyp] ) in the brain were suggested to possibly impact the biotransformation of xenobiotics or endogenous molecules in human epileptic subjects, [10] [11] [12] [13] [14] [15] a concept that transverses to several CNS pathologies. 14, [16] [17] [18] [19] [20] [21] However, the role of spontaneous seizure activity and status epilepticus (SE) in modifying brain Cyp expression remains to be fully clarified. Furthermore, the possibility that, during spontaneous seizures, changes in Cyp expression may occur in the liver, a primary drug metabolic site in the periphery, has never been investigated. This latter hypothesis fits the concept of a brain-peripheral cross talk, exporting pathophysiological signals beyond the brain's borders. This proposition could have a significant consequence by allowing pharmacokinetic aspects of drug regimens during CNS disease to be better defined or predicted. Previous studies in the epilepsy field have focused on peripheral aspects of disease (eg, blood biomarkers), but have neglected direct effects on peripheral organs. 7 In the present study, we asked whether spontaneous recurrent seizures and SE in mice are associated with hepatic and brain Cyp expression changes. We evaluated 2 experimental models to elicit SE (nonconvulsive and tonic-clonic) and spontaneous recurrent seizure (SRS), investigating changes in Cyp expression in the brain and liver. We focused on Cyp2e1 and Cyp3a, as their human homologues are responsible for the metabolism of a large array of antiepileptic medications. 14, 20, 22 We evaluated the existence of pathophysiological modifications previously suggested to impact Cyp expression, namely astrocytosis 20 and nuclear receptor [23] [24] [25] [26] [27] or corticosterone levels.
| MATERIALS AND METHODS

| Vertebrate animals
All experiments were performed according to the European Union (Council directive 86/609EEC) and institutional/local guidelines on laboratory animals' usage. Mice (male C57BL/6j, 8-10 weeks old) were housed on a 12-hour light/ dark cycle with food and water ad libitum. Animal protocols were approved by the French ethical committee for animal testing (05185.01; 0846.01 to NM and #8564 to FB). All efforts were directed at minimizing animal discomfort and to reduce the number of animals used (3R rule). operating the microsyringe. After injection, the cannula was left in place for an additional 2 minutes to avoid reflux. Sham mice were injected with 50 nL of 0.9% sterile NaCl. Mice were implanted with a bipolar electrode corresponding to the injection site. Mice were also equipped with 3 monopolar electrodes placed on the right frontoparietal cortex, whereas the reference was placed on the cerebellum (cortical electroencephalographic [EEG] traces not shown). Electrodes were secured on the skull using dental acrylic cement. After surgery, the animals were kept under observation for 8 hours to assess the behavioral changes corresponding to SE. [28] [29] [30] Generally, IH KA elicited nonconvulsive SE, with mild asymmetric clonic movements of the forelimbs along with deviations of the head, rotations, and periods of stillness. 31 In some cases, bilateral clonic seizures associated with rearing were observed. 30, 31 Video-EEG recording was performed using a Pinnacle Technology wired system (Lawrence, KS, USA). Signals acquisition was filtered at 40 Hz, and sampling set at 200-400 Hz. Video was synchronized to the EEG. Mice were monitored daily and for the next 5 consecutive weeks (at least 3 h/session) to detect SRS. The occurrence of SRS activity was characterized using EEG analysis (pClamp, Sirenia), and criteria were derived from previously published guidelines. [28] [29] [30] Briefly, (1) rhythmic sharp waves were selected when their amplitude was >2 9 baseline, (2) spike activity of >5-second duration was considered a seizure, and (3) 2 distinct seizures were separated by >1 second from each other. Figure 2 provides quantifications of seizure activity and the number of seizures calculated according to the above criteria and normalized by EEG recording time (hours). Scoring in Figure 2H ,H1 is proportional to the duration of the longest hippocampal discharges detected for each mouse during 3 consecutive EEG sessions performed between weeks 1 and 5. The latter method was previously described by Heinrich et al, 29 and it reflects the level of maturation of an epileptic network and epileptogenesis.
| Intraperitoneal KA injection
Mice were anesthetized using ketamine/xylazine and placed in a stereotaxic frame. IH bipolar electrodes were implanted. See above for surgery details. Behavior was scored according to the Racine scale during SE as induced by IP KA injection (KA, 25 mg/kg; stock solution 5 mg/mL KA in phosphate-buffered saline [PBS] , pH = 7 adjusted with NaOH 0.2 mol/L). Animals were selected when a generalized tonic-clonic SE associated with a loss of balance was observed (Stage VI Racine). We chose animals experiencing at least 3 tonic-clonic convulsive SEs (lasting at least 30-45 seconds over a period of 90 minutes).
The following groups of animals were generated using IH KA injections: sham control, and 24-72 hours, 1 week (n = 5-6/group), and 6 weeks post-KA (n = 9). Two separate series of animals were used to perform histology, Western blots, and real-time quantitative polymerase chain reaction (RT-qPCR; paraformaldehyde [PFA] fixed vs snap frozen), leading to a total of n = 20-24 9 2 mice (up to 1 week) and 9 9 2 mice (6 weeks). IP KA injections were also performed to obtain the following groups: sham control, 24-72 hours, and 1 week (n = 5-6 mice/group). There were 2 series (n = 20-24 9 2 mice). Samples obtained from 24-and 72-hour groups were pooled together to increase the number of animals. Mice were processed as follows: (1) intracardiac perfusion with 4% PFA + overnight postfixation for brain and liver histology; livers were transferred to 30% EtOH; (2) intracardiac perfusion with PBS, and liver and hippocampi were snap frozen for Western blot and RT-qPCR analysis; and (3) blood samples were obtained (immediately after SE or at SRS) from the left cardiac ventricles prior to PBS/PFA perfusions. Model efficiency was as follows: (1) IH KA nonconvulsive SE induction rate, 100%; mortality 2 of 52 (~4%) occurring during SE; (2) IP KA convulsive SE induction rate, 75%; mortality, 9 of 34 (~25%) during SE or 24 hours after.
| RT-qPCR
Total cellular RNA was isolated and genomic DNA contamination was removed using the RNeasy Mini RNA isolation kit (Qiagen, Venlo, The Netherlands). Two micrograms of total RNA was reverse-transcribed using random hexamers and the MMLV reverse transcriptase kit (Invitrogen, Waltham, MA, USA). RT-qPCR was performed in a LightCycler 480 apparatus (Roche Diagnostics, Meylan, France) with a SYBR green based detection assay (Roche-Ventana, Oro Valley, AZ, USA). Reactions were conducted in a 10-lL volume of 50 ng cDNA, 300 nmol/L of each primer, and 5 lL of SYBR Green PCR Master Mix at 95°C for 10 minutes, 40 cycles of denaturation at 95°C for 10 seconds, annealing at 61°C for 20 seconds, and elongation at 72°C for 20 seconds. Amplification specificity was confirmed for each sample by determining the melting curve. The levels of cDNA were quantified by the comparative threshold cycle method using b-actin and/or glyceraldehyde 3-phosphate dehydrogenase as an internal standard. Primers are listed in Table S1 . Figure S1B shows examples of reporter genes (C t ) determined in 3 separate experiments using samples (eg, control and SRS), confirming consistency and stability of the readouts.
| Western blots
Liver samples were homogenized in buffer (500 lL) containing: 0.1% sodium dodecyl sulfate, protease inhibitor cocktail (Promega, Madison, WI, USA), 50 mmol/L Tris-HCL (pH 7.4), 10 mmol/L ethylenediaminetetraacetic acid (EDTA), 1 mmol/L Na 3 VO 4 , 40 mmol/L sodium pyrophosphate, 50 mmol/L NaF, and 1 mmol/L dithiothreitol. After centrifugation (15 000 g for 10 minutes), samples were separated by electrophoresis and then transferred onto a nitrocellulose membrane. After 1 hour of blocking, the membranes were probed at 4°C (overnight) with a rabbit monoclonal anti-Cyp2e1 (1:1000; Abcam ab151544, Cambridge, United Kingdom) or rabbit polyclonal to human anti-Cyp3a4 also recognizing mouse Cyp3a (1:2000; Abcam ab176310) and a mouse anti-actin (1:10 000; Abcam ab6276). Goat anti-rabbit (1:4000; Jackson ImmunoResearch, West Grove, PA, USA, 111-035-003) and goat anti-mouse horseradish peroxidase-conjugated (1:4000; Jackson ImmunoResearch, 115-035-003) antibodies were used for Cyp2e1, Cyp3a, or b-actin. Immunoreactivity was detected with an enhanced chemiluminescence method (ECLTM plus detection reagent; GE Healthcare, Little Chalfont, United Kingdom), and signals were quantified using ImageJ (National Institutes of Health, Bethesda, MD, USA).
| Microsomal fraction isolation and enzyme activity assay
Microsome preparations were obtained from hepatic tissues using a Microsome Isolation Kit (product #K249 Biovision, CA, USA). Mice (n = 9 SRS and n = 6 control) were perfused intracardially with PBS, and the livers were dissected and homogenized using the reagents provided by the vendor. After centrifugation, the microsomal pellets were suspended in storage buffer and kept at À80°C. Protein concentration was determined using a NanoDrop 2000 (absorbance at 280 nm; Thermo Fisher Scientific, Waltham, Mass, USA). Cyp3a4 activity was quantified using a P450-Glo assay (#V9001, Promega, Madison, Wisconsin, USA). Briefly, microsomal fractions (96-well plate) were combined with a selective substrate (luciferin) for 10 minutes at 37°C. The enzymatic reaction was initiated using a nicotinamide adenine dinucleotide phosphate regenerating system supplied by the vendor. A luciferin detection reagent was added, and the luminescent signal was quantified (Infinite 200, Tecan, M€ annedorf, Switzerland; integration time = 1000 ms/well). The standard curve was determined using D-luciferin (0.016, 0.08, 0.4, 2, and 10 lmol/L).
| Corticosterone measurement
Blood samples were collected from the left cardiac ventricle using heparinized needle/containers and centrifuged (425 g, 10 minutes at 4°C). For each sample, the serum was separated and stored at À80°C. Quantitative determination of corticosterone was performed using a colorimetric competitive enzyme immunoassay (Corticosterone EIA kit, Cat. No. ADI-900-097, Enzo Life Sciences , Farmingdale, New York, USA) according to the vendor protocol.
| Brain and liver immunohistochemistry
All liver samples were processed for dehydration/paraffin embedding using a Peloris automaton (Leica, Wetzlar, Germany). Briefly, 4-lm paraffin sections were stained using a Discovery XT automaton (Roche-Ventana) and the ChromoMap DAB detection kit (Roche-Ventana; 05266645001). Tris/EDTA pH 8-8.5 antigen retrieval was performed, and Cyp immunoreactivity was detected using the following rabbit polyclonal antibodies: anti-Cyp2e1 (1:50; Abcam; ab28146) or anti-Cyp3a4 (1:200; Abcam; ab176310). After 1 hour of incubation (37°C), samples were treated (16 minutes at 37°C) with an OmniMap antirabbit antibody (Roche-Ventana; 05269679001). Liver sections were counterstained with hematoxylin (Hematoxylin II, 05277965001; bluing reagent, 05266769001; RocheVentana). Slides were dehydrated and coverslipped with DPX mounting media. Images were acquired using a Nanozoomer scanner (Hamamatsu, Japan) in bright field condition (209). Quantification of Cyp2e1 and Cyp3a signals was performed on randomly chosen whole liver slices. A Fiji semiautomatic routine was used to calculate pixel area normalized by total slice area 9 100.
Brain coronal sections were collected and washed 3 times with PBS. Sections were blocked using PBS containing 0.25% triton and 20% normal horse serum (1 hour, room temperature). Slices were incubated overnight at 4°C with primary antibody (PBS containing 0.1% triton): antiCyp2e1 (polyclonal rabbit, 1:200; Abcam, Ab28146), antiCyp3a4 (polyclonal rabbit, 1:100; Abcam, Ab176310), anti-glial fibrillary acidic protein (GFAP; polyclonal chicken, 1:1000, Abcam, Ab4674), anti-IBA1 (polyclonal rabbit, 1:2000; 019-19741, Wako, Richmond, VA, USA). After 3 washes, secondary antibodies were incubated for 2 hours (room temperature). Cyp2e1 and Cyp3a immunoreactivity was imaged using a fluorescent microscope (Apotome Z-stacks 209 and 409; montage 109; AxioImager Z1, Zeiss, Oberkochen, Germany).
| Statistics
Data were analyzed using parametric or nonparametric (Mann-Whitney) tests depending on normality distribution (Shapiro-Wilcox). Student t test with equal variances was used for groups of 2, when relevant. Linear plots were analyzed using Pearson (r values) correlation analyses. In all cases, significance was ˂.05. Statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Prism Software, San Diego, CA, USA) or Origin Microcal (Northampton, MA, USA).
| RESULTS
| Hippocampal and hepatic Cyp overexpression during spontaneous recurrent seizures
We asked whether brain Cyp expression was modified during SRSs as elicited by unilateral IH KA injection. 30 Hippocampal Cyp2e1 and Cyp3a13 transcripts were significantly increased in SRS mice as compared to control ( Figure 1A1,A2 ). Cyp3a13 is a gene isoform coding for the Cyp3a protein in mice. 21 Cyp and GFAP transcript increase was significant in the ipsilateral as compared to the contralateral hippocampi, where Cyp transcripts did not change (Fig. S1A,A2) . A positive correlation was found between GFAP immunoreactivity and Cyp transcript levels ( Figure 1B,B1 ). Cyp3a11 isoform transcripts were significantly lower (RT-qPCR, C t > 33) than Cyp3a13 and did not change between experimental groups (not shown). Montages in Figure 1C ,C1 depict the typical brain topography of GFAP hippocampal immunoreactivity occurring during SRS. Cyp2e1 expression was increased at SRS (ipsilateral > contralateral; Figure 1D ,D1), colocalizing with GFAP ( Figure 1F ). Cyp3a expression was increased at SRS ( Figure 1G ). Z-plane reconstructions indicate an example of Cyp2e1 expression at the endfeet glial-microvascular interface ( Figure 1H ). Although causality is not implied, these results indicate GFAP immunoreactivity concomitant to hippocampal Cyp overexpression during spontaneous recurrent seizures. The hepatic levels of Cyp2e1 and Cyp3a13 transcripts ( Figure 2C ,D shows examples of Cyp2e1 and Cyp3a immunohistochemistry performed on hepatic tissues obtained from control and SRS mice. Hepatic Cyp3a11 transcripts were detected, although they did not change (data not shown). Abundance of Cyp mRNA levels in the liver as compared to the hippocampi was confirmed as an internal control (Fig. S1C,C1) . Examples of IH EEG traces recorded 1 week after IH KA and during SRS are shown in Figure 2E ,E1,F, color-coded to examples of scoring plots ( Figure 2G,G 1) . Hepatic Cyp2e1 and Cyp3a expression positively correlated with SRS scores (Figure 2H-H2 
| SE dysregulates hippocampal and hepatic Cyp expression
We examined whether Cyp expression was impacted early after SE (convulsive or not 30, 31 ). Hippocampal Cyp expression was qualitatively evaluated up to 1 week after IH or IP KA injections (Figure 3 ). The combination of the 2 models allows overcoming confounding factors such as (1) direct KA hepatic/brain tissue effects unrelated to seizures and (2) tissue lesions due to cannula/electrode insertion. IBA1 and GFAP activation was confirmed ( Figure 3A) . We found an incremental Cyp2e1 and Cyp3a astrocytic expression consequent to either IH ( Figure 3C ) or IP (Figure 3D ,E) KA-induced SE. Z-stack reconstructions confirmed GFAP + astrocyte Cyp2e1 and Cyp3a colocalization, and neuronal expression of Cyp3a was also observed (arrows in Figure 3E ). IBA1 + microglial activation did not colocalize with Cyp expression. Table 1 summarizes RTqPCR data. The effect of SE on hepatic Cyp levels was also investigated. No significant changes or a transient decrease in Cyp2e1 or Cyp3a13 transcripts was found 24-72 hours post-SE (IH and IP KA; Table 1 ). Figure 4A ,B shows modulation of Cyp proteins occurring 24-72 hours after convulsive SE (IP KA). In particular, qualitatively decreased Cyp3a and increased Cyp2e1 protein expression was detected after SE in the liver. Figure S1D -D3 provides box plot examples of Cyp transcript and protein levels in the IH KA model. These results only suggest short-term and differential patterns of hepatic Cyp modulation depending on SE.
| Serum corticosterone and hepatic nuclear receptor levels
In peripheral organs, the expression of Cyp enzymes is directly controlled by upstream xenobiotic (nr1i) and glucocorticoid (GR) nuclear receptors. 26, 27 The latter are activated by endogenous ligands, for example, cortisol in humans and corticosterone in mice. 32 Interestingly, clinical evidence indicates a postictal cortisol increase in the blood of epileptic patients. [33] [34] [35] We therefore performed an initial analysis of nuclear receptor expression and corticosterone levels following SE or during SRS in mice. The hepatic expression of GR and nr1i transcripts was stable throughout disease progression ( Figure 5A-C) . Figure 5D depicts Table 1 for real-time quantitative polymerase chain reaction Cyp transcript levels.
changes in serum corticosterone occurring shortly after SE as induced by IP or IH KA injections. Mean corticosterone level was increased during SRS, although a significant variability existed between mice. We are aware that corticosterone half-life is short and that the exact interval between the last SRS and blood collection could not be accounted for. We speculate that hepatic Cyp overexpression during SRS may result from corticosterone fluctuations activating specific nuclear receptors in the liver.
| DISCUSSION
The results presented indicate the upregulation of specific Cyp in the liver and hippocampi during SRS. Cyp2e1 and Cyp3a13 (Cyp3a protein) expression changes in response to seizures could affect both peripheral and CNS drug biotransformation routes. This study was designed to elucidate whether a chronic disease is sufficient to modify the expression of biotransformation enzymes in the periphery in the absence of confounding factors, for example, drugs targeting seizures and comorbidities. Thus, it is recognized that cytochrome enzyme expression or activity can be induced by xenobiotics. 21 Whereas human brain specimens can be available from surgical procedures performed to relieve drug-resistant seizures, access to the patient's peripheral organs (eg, liver) is improbable. The use of experimental models of seizures circumvents the latter problem.
| Cyp expression and brain pathology
Accumulating evidence indicates the expression of Cyp in brain cells, with results varying and depending on the species and sample preparation methods. [10] [11] [12] 14, 36 The original report of Cyp expression at periventricular brain structures 12 was followed by evidence for Cyp and nuclear receptor (NR) expression in isolated microcapillaries and in isolated brain primary cells or tissues. 10, 14, 36 Our results focus on Cyp2e1 and Cyp3a as they are implicated in the phase 1 metabolism of numerous antiepileptic drugs 14, 22 and modified in drug-resistant epileptic human brain Cyp overexpression during SRS. GFAP mRNA increase during SRS was less prominent in the contralateral as compared to the ipsilateral hippocampi (IH KA) and not associated with significant Cyp changes (Fig. S1A3,A4 ). Our results align with the pathophysiological significance of Cyp enzymes in CNS diseases, including Parkinson disease, alcohol or drug dependence, and neurodegenerative diseases. [16] [17] [18] [19] [20] Although expressed at lower levels in the brain as compared to the liver, neurogliovascular cytochromes are localized in the immediate proximity of neuronal drug targets, possibly representing a second line of xenobiotic biotransformation, with a potential impact on CNS drug efficacy or neurotoxicology. Table 1 and Figure S1D . Astrocyte Cyp overexpression is consistent with drug biotransformation occurring at the cerebrovascular interface (eg, endfeet) and in the parenchyma. Our results also confirm Cyp expression in neurons, specifically Cyp3a. The latter fits evidence previously described in humans and rodents. 37 
| Peripheral-CNS interplay in health and disease
A cause and effect relation between peripheral diseases and CNS pathologies is clinically recognized. For instance, metabolic disorders, diabetes, or sustained peripheral inflammation can determine neurological symptoms, including psychiatric illnesses and seizures. In this case, cerebrovascular permeability is evoked as one of the participating culprits. 7, 40 The opposite route (ie, brain-driven peripheral changes) remains relatively understudied. The activation of vagal nerve or sympathetic and parasympathetic pathways in response to seizures has been proposed in epilepsy. 41 Our results support further studies to determine whether stress molecules (corticosterone, epinephrine, norepinephrine, etc) released post-SE or during SRS can activate nuclear receptors in peripheral organs, resulting in Cyp expression changes. Thus, GR and nr1i2-PXR directly regulate Cyp3a transcription. 26, 27, 32 This hypothesis is supported by the clinical evidence of increased cortisol levels corresponding to ictal events in epileptic subjects. [33] [34] [35] We speculate that the hypothalamus-pituitary-adrenal (HPA) axis could also be involved, possibly explaining the fluctuation of stress hormones in blood. The latter remains to be investigated.
| Pitfalls and conclusions
We are aware that a number of caveats exist in the presented study. In particular, these include (1) a lack of comprehensive functional assays evaluating Cyp metabolism of antiepileptic drugs during epileptogenesis and SRS, (2) the temporal correlation between SRS and corticosterone levels was not investigated, (3) the mechanism of corticosterone changes (eg, HPA axis and adrenal cortex activation) was only speculated, (4) corticosterone entry in the CNS and its effect was not evaluated, and (5) other peripheral organs of drug biotransformation (eg, intestine) were not studied. The latter exceed the capacity of our current study but could be evaluated as a continuation of this research.
In conclusion, our results indicate that hepatic and brain Cyp mechanisms of drug biotransformation are modified during SRS. The existence of a mechanistic link between the peripheral and brain changes remains to be defined. The functional significance of Cyp regulation in epilepsy is important, as we could improve drug efficacy and predict side effects. Nuclear receptors or inflammatory pathways may contribute to the changes in hepatic and brain Cyp expression during seizures and are therefore 2 potential targets to consider. Epilepsie (FFRE-FR1) (N.M.). We would like to thank Dr. Badreddine Boussadia for the initial discussion of the experimental plan; Dr. Antoine DePaulis for sharing his know-how on experimental models of seizures; and Dr. Laurent Givalois for sharing expertise inherent to stress hormone biology and monitoring.
